The United States Patent and Trademark Office recently granted a groundbreaking patent for “Unshielded pulsed pump magnetometers for biomagnetic measurements” under Patent No. 12,616,402. This revolutionary technology was developed and patented by Twinleaf LLC, a leading quantum sensor and physics-based technology developer headquartered in Plainsboro, New Jersey. The invention represents a monumental shift in how scientific and medical institutions capture weak magnetic fields generated by human biological activity.
By engineering a novel approach to magnetic field tracking, this system opens the door to widespread clinical deployment of advanced biomagnetic diagnostics without conventional infrastructure burdens. For a closer look at their complete product ecosystem and open-source software libraries, you can visit the official Twinleaf LLC website. Due to its potential to transform decentralized neurological and cardiac care, this innovation was proudly honored as the New Jersey State Patent of the Month for June 2026.
Why the Unshielded Pulsed Pump Magnetometer is So Innovative
Historically, capturing biomagnetic signals (such as magnetoencephalography for brain activity or magnetocardiography for heart function) required Superconducting Quantum Interference Device sensors or zero-field optically pumped magnetometers. While highly precise, these traditional tools demand extreme environmental isolation. They require cryogenic cooling systems to maintain superconducting states and must operate within expensive, multi-layer magnetically shielded rooms to prevent external environmental noise from drowning out the body’s faint magnetic signals. This has confined advanced biomagnetic imaging to specialized research hospitals and heavily funded universities.
Twinleaf LLC’s patented Pulsed Pump Magnetometer completely changes this paradigm by providing vastly superior dynamic range, exceptional linearity, and unmatched sensitivity compared to legacy sensors. The high dynamic range allows an array of these sensors to faithfully measure and cancel out intense background magnetic noise (such as geomagnetic fields, urban power lines, and local electronics) through sophisticated noise decorrelation and covariance modeling. Consequently, clinical teams can perform high-fidelity biomagnetic imaging in unshielded, real-world environments like standard medical offices, eliminating the need for cryogenics and massive shielding infrastructure.
Earning New Jersey’s Patent of the Month for June 2026
The selection of Twinleaf LLC’s patent as the New Jersey State Patent of the Month for June 2026 highlights the state’s vibrant role in pioneering next-generation medical device technology. Based in Plainsboro, Twinleaf exemplifies the high-tech research and development culture flourishing within the Garden State. This patent earned the prestigious monthly honor because it provides a practical, scalable solution to a long-standing bottleneck in medical imaging. By turning complex quantum mechanics into a compact, office-ready sensor platform, this technology promises to foster regional economic growth, drive advanced manufacturing, and dramatically expand patient access to low-cost, non-invasive diagnostic evaluations for cardiac arrhythmias and neurological disorders.
U.S. R&D Tax Credit Eligibility for Practical Applications
The commercial design, refinement, and practical deployment of Twinleaf LLC’s unshielded pulsed pump magnetometer technology serve as prime candidates for the U.S. Research and Development Tax Credit under Internal Revenue Code Section 41. To qualify for this federal incentive, a company’s activities must meet a strict four-part test: the work must be technical in nature, rely on hard sciences such as physics or electrical engineering, eliminate technical uncertainty, and utilize a repetitive process of experimentation to improve a product’s functionality, performance, or reliability. When engineering real-world applications of this patent, businesses engage in qualified activities when they design custom multi-sensor configurations for target clinical settings, optimize noise-cancellation algorithms for localized biomagnetic source imaging, or develop specialized non-magnetic housing to prevent sensor crosstalk. The qualified research expenses associated with these initiatives, including the wages of specialized software engineers and quantum physicists, costs of prototype components like microfabricated alkali-vapor cells, and direct third-party testing expenditures, can be claimed to significantly offset tax liabilities and fuel further technological innovation.
